Digoxin immune fab
Bottle of digoxin immune fab | |
| Clinical data | |
|---|---|
| Trade names | Digibind, others |
| AHFS/Drugs.com | Consumer Drug Information |
| Routes of administration | IV infusion, injection |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Onset of action | 30 min[2] |
| Elimination half-life | 15 hours for DigiFab, 23 hours for Digibind |
| Duration of action | 15 to 20 hrs[2] |
| Excretion | Kidney |
| Identifiers | |
IUPAC name
| |
| DrugBank | |
| ChemSpider |
|
| ChEMBL | |
| Chemical and physical data | |
| Formula | C2085H3223N553O672S16 |
| Molar mass | 47301.88 g·mol−1 |
| (what is this?) (verify) | |
Digoxin immune fab or digoxin-specific antibody is an antidote for overdose of digoxin.[3] It is made from immunoglobulin fragments from sheep that have already been immunized with a digoxin derivative, digoxindicarboxymethoxylamine (DDMA). Its brand names include Digibind (GlaxoSmithKline) and DigiFab (BTG plc).
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
- ^ a b "digoxin immune Fab (ovine)". www.glowm.com. Retrieved 8 September 2020.
- ^ DiDomenico RJ, Walton SM, Sanoski CA, Bauman JL (April 2000). "Analysis of the use of digoxin immune fab for the treatment of non-life-threatening digoxin toxicity". Journal of Cardiovascular Pharmacology and Therapeutics. 5 (2): 77–85. doi:10.1053/XV.2000.5590. PMID 11150387. S2CID 33064518.